OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Agnes Shanley is senior editor of BioPharm International.
Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.
Related Content:
News | Biosimilars and Biobetters | Manufacturing, Biosimilars and Biobetters | Biopharma News